MedTrace Logo

A Study of PET/CT Imaging Using INR101 Injection in Healthy Male Subjects and Patients With Suspected Prostate Cancer

NCT06472531 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2024-10-30

No results posted yet for this study

Summary

Phase I/II study in the management of Healthy Male Subjects and patients with suspected prostate cancer.

Conditions

  • Healthy Male Subjects
  • Suspected Prostate Cancer

Interventions

DRUG

INR101

• 9±1 mCi of INR101 will be injected intravenously prior to perform the PET/CT

DRUG

INR101

* 9±1 mCi of INR101 will be injected intravenously prior to perform the PET/CT * 7±1 mCi of INR101 will be injected intravenously prior to perform the PET/CT

Sponsors & Collaborators

  • Yunhe Pharmaceutical (Tianjin) Co., Ltd

    lead OTHER

Principal Investigators

  • Jinming Zhang, Ph.D · The First Medical Center of the General Hospital of the Chinese People's Liberation Army

  • Jigang Yang, Ph.D · Beijing Friendship Hospital

  • Fugeng Liu, BD · Beijing Hospital

  • Xuejuan Wang, Ph.D · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-05-23
Primary Completion
2024-09-30
Completion
2024-10-10

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06472531 on ClinicalTrials.gov